



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30/09/2013

PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Six Months ended		Previous year ended
		30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	15,141.23	10,866.96	5,025.90	26,008.19	12,078.62	25,788.46
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net) (a)+(b)	15,141.23	10,866.96	5,025.90	26,008.19	12,078.62	25,788.46
2	Expenses						
	a) Cost of materials consumed	4,200.48	3,374.55	1,683.66	7,575.03	3,828.29	8,827.40
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(727.64)	14.69	(301.91)	(712.95)	28.93	(559.63)
	d) Employee benefits expense	759.79	779.83	562.82	1,539.62	1,214.55	2,537.70
	e) Depreciation and amortisation expense	221.92	209.48	170.05	431.40	353.28	786.72
	f) Other expenses - Manufacturing Expenses	1,288.32	1,159.51	893.71	2,447.83	1,742.26	3,904.81
	- Selling Expenses	305.88	110.47	83.58	416.35	183.79	502.80
	- Administrative Expenses	374.80	332.38	596.52	707.18	1,113.94	1,787.50
	- R & D Expenses	1,789.79	793.87	682.80	2,583.66	1,557.48	3,469.32
	- Provision for MTM on Forward contracts	8.59	(1.53)	(314.27)	7.06	(63.31)	-
	Total expenses	8,221.93	6,773.25	4,056.96	14,995.18	9,959.21	21,256.62
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	6,919.30	4,093.71	968.94	11,013.01	2,119.41	4,531.84
4	Other Income	11.41	315.53	(39.26)	326.94	13.21	104.34
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	6,930.71	4,409.24	929.68	11,339.95	2,132.62	4,636.18
6	Finance costs	341.28	319.06	289.75	660.34	611.67	1,350.94
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	6,589.43	4,090.18	639.93	10,679.61	1,520.95	3,285.24
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 + 8)	6,589.43	4,090.18	639.93	10,679.61	1,520.95	3,285.24
10	Tax Expenses	2,034.75	1,112.99	(8.96)	3,147.74	75.72	201.29
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 - 10)	4,554.68	2,977.19	648.89	7,531.87	1,445.23	3,083.95
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	4,554.68	2,977.19	648.89	7,531.87	1,445.23	3,083.95
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes minority interest and share of profit / (loss) of associates and (13 + 14 + 15)	4,554.68	2,977.19	648.89	7,531.87	1,445.23	3,083.95
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,168.29	1,168.29	1,167.32	1,168.29	1,167.32	1,168.29
18	Reserve excluding Revaluation Reserves (as per balance sheet of previous accounting year)	-	-	-	-	-	14,277.70
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	3.90	2.55	0.56	6.45	1.24	2.64
	b) Diluted	3.90	2.55	0.56	6.45	1.24	2.64
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	3.90	2.55	0.56	6.45	1.24	2.64
	b) Diluted	3.90	2.55	0.56	6.45	1.24	2.64

PART - II		30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
A	PARTICULARS OF SHAREHOLDING	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Public share holdings						
	a. Number of shares	41,171,212	41,171,212	42,679,160	41,171,212	42,679,160	41,993,960
	b. Percentage of share holding	35.24%	35.24%	36.56%	35.24%	36.56%	35.94%
2	Promoters and promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	75,657,576	75,657,576	74,052,828	75,657,576	74,052,828	74,834,828
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.76%	64.76%	63.44%	64.76%	63.44%	64.06%
Particulars		3 months ended (30/09/2013)					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	0					
	Received during the quarter	32					
	Disposed of during the quarter	32					
	Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							Rs. in lakhs
PARTICULARS	Quarter ended			Six Months ended		Year ended	
	30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013	
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	
1	SEGMENT REVENUE						
	a) Manufacturing (CRAMS)	14,742.29	10,688.52	4,359.17	25,430.81	10,874.12	24,456.23
	b) Services (DDDSS)	398.95	178.43	666.73	577.38	1,204.50	1,332.24
	c) Research & Development	-	-	-	-	-	-
	Net sales/income from operations	15,141.24	10,866.95	5,025.90	26,008.19	12,078.62	25,788.47
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
	a) Manufacturing (CRAMS)	8,859.93	5,179.70	1,417.44	14,039.63	3,911.81	9,176.71
	b) Services (DDDSS)	213.02	15.83	406.29	228.85	637.49	370.00
	c) Research & Development	(1,789.79)	(793.87)	(682.80)	(2,583.66)	(1,557.48)	(3,469.32)
	TOTAL	7,283.16	4,401.66	1,140.93	11,684.82	2,991.82	6,077.39
	Less: (i) Interest	194.13	217.43	261.41	411.56	559.55	1,174.34
	(ii) Other Un-allocable expenses net off	499.60	94.04	239.59	593.64	911.32	1,617.81
	(iii) un-allocable Income	-	-	-	-	-	-
	Profit Before Tax	6,589.43	4,090.19	639.93	10,679.62	1,520.95	3,285.24
3	CAPITAL EMPLOYED (Segment Assets - Segment Liabilities)						
	a) Manufacturing (CRAMS)	23,091.94	18,132.77	10,856.83	23,091.94	10,856.83	13,212.39
	b) Services (DDDSS)	3,264.03	3,300.93	3,081.55	3,264.03	3,081.55	3,093.23
	c) Research & Development	2,259.21	2,757.53	2,359.18	2,259.21	2,359.18	2,503.65
	d) Net assets which are not segmented and used commonly	(5,637.34)	(5,768.06)	(2,100.18)	(5,637.34)	(2,100.18)	(3,363.29)
	TOTAL	22,977.84	18,423.17	14,197.38	22,977.84	14,197.38	15,445.98

Notes:

- The above audited results were approved and taken on record at the Board of Directors' meeting held on 11th November, 2013.
- Previous years figures have been regrouped/reclassified whenever necessary.
- Suven Nishtaa Pharma Pvt Ltd., the 100% subsidiary, has been merged w.e.f. 1st January, 2012 and accordingly the results have been prepared. Hence the current quarter figures are not comparable with the previous corresponding quarter figures.
- The limited review of quarter 2 results has been done by the Statutory Auditors.

For SUVEN LIFE SCIENCES LTD



Place : Hyderabad
Date : 11th November, 2013

VENKAT JASTI
Chairman & CEO

We Deliver



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Standalone Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing agreement

(Rs. In lakhs)

	Particulars	Half year Ended	
		30/09/2013	31/03/2013
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,168.29	1,168.29
	(b) Reserves and Surplus	21,809.56	14,277.69
	Sub-total - Shareholders' funds	22,977.85	15,445.98
2	Non-current liabilities		
	(a) Long-term borrowings	5,585.08	6,418.33
	(b) Deferred tax Liability (net)	1,557.08	-
	(c) Long-term provisions	157.78	157.78
	Sub-total - Non-current liabilities	7,299.94	6,576.11
3	Current liabilities		
	(a) Short-term borrowings	3,003.80	2,782.59
	(b) Trade payables	3,616.10	3,613.53
	(c) Other current liabilities	5,341.29	3,611.53
	(d) Short-term provisions	2,622.78	1,382.72
	Sub-total - Current liabilities	14,583.97	11,390.37
	TOTAL - EQUITY AND LIABILITIES	44,861.76	33,412.46
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	17,890.09	16,566.30
	(b) Non-current investments	0.15	0.15
	(c) Deferred tax assets (net)	-	1,569.62
	(d) Long-term loans and advances	843.75	943.83
	Sub-total - Non-current assets	18,733.99	19,079.90
2	Current assets		
	(a) Current investments	770.37	7.12
	(b) Inventories	6,715.07	5,381.43
	(c) Trade receivables	9,687.94	2,377.76
	(d) Cash and cash equivalents	1,736.84	2,178.69
	(e) Short-term loans and advances	7,182.66	4,367.88
	(f) Other current assets	34.89	19.68
	Sub-total - Current assets	26,127.77	14,332.56
	TOTAL - ASSETS	44,861.76	33,412.46

For Suven Life Sciences Ltd

Venkat Jasti
Chairman & CEO